Advertisement

Picture EBD Group BIO-Europe 2021 Digital BEU2021 650x80
Organisation › Details

Dopavision GmbH

Dopavision is pioneering the development of digital therapeutics. As its lead product, the Company is developing a game-changing therapeutic for childhood myopia which can be seamlessly and invisibly integrated into the use of a smartphone. Myopia, or shortsightedness, is a visual condition that affects on average every third person globally, a share that has increased rapidly during the last two decades. It has grown to alarming proportions in Asia where prevalence rates, e.g. in Singapore, have reached 80% among young adults. High childhood myopia imposes a significant risk to cause visual impairment and even blindness later in life. Dopavision´s goal is to develop a clinically validated therapy to halt myopia progression in children and adolescents. Founded in 2017 by Hamed Bahmani, Dopavision has so far raised €14.7 million in private equity and public grants and is backed by top-tier international investors such as Seventure Partners, Novartis Pharma and Boehringer Ingelheim Venture Fund. Dopavision is supported by the German government via the “Industrie-in-Klinik” program of the German Federal Ministry of Education and Research BMBF (Aktionsfeld “Gesundheitswirtschaft im Rahmenprogramm Gesundheitsforschung”, Fo¨rderkennzeichen/contract number 13GW0256). *

 

Period Start 2017-11-08 established
Products Industry digital health
  Industry 2 digital therapeutic (dTx)
     
Region Region Berlin
  Country Germany
  Street 68 Friedrichstr.
  City 10117 Berlin
    Address record changed: 2021-07-16
     
Basic data Employees n. a.
     
    * Document for �About Section�: Dopavision GmbH. (7/14/21). "Press Release: Dopavision Closes €12 Million Series A Round to Advance Digital Childhood Myopia Therapeutic Through Clinical Trials". Berlin.
     
   
Record changed: 2021-07-16

Advertisement

Picture EBD Group BIO-Europe 2021 Time to Register 650x200

More documents for Dopavision GmbH


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture [iito] Plain Stupid Simple 650x80px




» top